HR 8005 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances, and for other purposes.
Summary
- Amends the Controlled Substances Act to prohibit certain acts related to counterfeit fentanyl and methamphetamine substances
- Defines counterfeit fentanyl or methamphetamine substances as controlled substances falsely marketed or sold under another product's trademark or name
- Requires the DEA to establish and implement a comprehensive plan within 180 days to address counterfeit fentanyl and methamphetamine substances
- Requires the DEA plan to include law enforcement strategies, education and prevention efforts, and evaluation of public awareness campaigns like "One Pill Can Kill"
- Requires the Attorney General to submit annual reports to Congress on counterfeit fentanyl and methamphetamine seizures, charges, and convictions
- Requires reports to include data on pill-form substances, geographic and temporal information, and prevention measures being undertaken
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Rep. Evans, Gabe [R-CO-8] (R-CO)
Money behind the sponsor
Top reported contributors to Gabe Evans’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- HASELDEN CONSTRUCTION $13,513
- BT CONSTRUCTION $11,600
- STARKEY HEARING TECHNOLOGIES $9,900
- FISHER INVESTMENTS $9,900
- SPIERER WOODWARD $9,900
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Gabe Evans → · Outside spending →
Actions (5)
- Jul 15, 2026 Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote. · house
- Jul 15, 2026 Subcommittee Consideration and Mark-up Session Held · house
- Mar 19, 2026 Referred to the Subcommittee on Health. · house
- Mar 19, 2026 Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Mar 19, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Committee action
What happened to this bill in committee — the meetings where it was considered and every recorded vote taken on it.
Meetings where this bill was on the agenda
Full text
IN THE HOUSE OF REPRESENTATIVES
March 19, 2026
Mr. Evans of Colorado introduced the following bill; which was referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Stop Pills That Kill Act”.
SEC. 2. DEFINITION.
In this Act, the term “counterfeit fentanyl or methamphetamine substance” means a substance that—
(1) contains fentanyl, any analogue of fentanyl, or methamphetamine; and
(2) is marketed under, sold under, or falsely bears the trademark, trade name, or other identifying mark, imprint, number, or any likeness thereof of another product.
SEC. 3. PROHIBITED ACTS.
Section 403(d)(2) of the Controlled Substances Act (21 U.S.C. 843(d)(2)) is amended, in the matter preceding subparagraph (A), by inserting “, fentanyl, an analogue of fentanyl, or a counterfeit substance” after “methamphetamine”.
SEC. 4. COMPREHENSIVE PLAN.
Not later than 180 days after the date of enactment of this Act, the Administrator of the Drug Enforcement Administration shall establish and implement an operation and response plan to address counterfeit fentanyl or methamphetamine substances that includes—
(1) strategies to enable and empower Federal law enforcement efforts to investigate and seize counterfeit fentanyl or methamphetamine substances;
(2) specific ways that education and prevention efforts to stop the use of counterfeit fentanyl or methamphetamine substances will be increased, including how—
(A) ongoing efforts, such as Operation Engage, are effective in increasing education and prevention; and
(B) how the efforts described in subparagraph (A) are tailored to youth and teen access; and
(3) an audit of current campaigns, including the “One Pill Can Kill” campaign, on counterfeit fentanyl or methamphetamine substances, including a review of data and other available information on how the campaigns can be tailored, adjusted, or improved to better address the flow of counterfeit fentanyl or methamphetamine substances.
SEC. 5. REPORT TO CONGRESS.
(a) Report.—Not later than 1 year after the date of enactment of this Act, and every year thereafter, the Attorney General, in consultation with the Administrator of the Drug Enforcement Administration and Director of the Office of National Drug Control Policy, shall submit to Congress a report on information regarding the collection and prosecutions of counterfeit fentanyl or methamphetamine substances.
(b) Contents.—The report required under subsection (a) shall include the following:
(1) Data on the aggregate number of counterfeit fentanyl or methamphetamine substances seized and collected by Federal law enforcement agencies.
(2) A breakdown on how many counterfeit fentanyl or methamphetamine substances are in pill form.
(3) A breakdown on which illicit substances are present in the counterfeit fentanyl or methamphetamine substances that are in pill form.
(4) Data outlining where and when counterfeit fentanyl or methamphetamine substances were seized.
(5) Data on the charges filed pursuant to paragraph (1) or
(2) of section 401(a) of the Controlled Substances Act (21 U.S.C. 841(a)) in relation to a counterfeit fentanyl or methamphetamine substance, particularly in pill form, unless disclosure of the data would—
(A) require unsealing an indictment; or
(B) undermine investigations and charges brought by the Department of Justice.
(6) Data on the convictions and sentences against those who are found guilty under paragraph (1) or (2) of section 401(a) of the Controlled Substances Act (21 U.S.C. 841(a)) as it pertains to counterfeit fentanyl or methamphetamine substances, particularly those in pill form.
(7) Any prevention measures that the Department of Justice, Drug Enforcement Administration, or Office of National Drug Control Policy are undertaking to limit and reduce the spread of counterfeit fentanyl or methamphetamine substances in pill form, including ongoing public awareness campaigns. <all>
Comments